252 related articles for article (PubMed ID: 16570152)
1. Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Matsue K; Takeuchi M; Koseki M; Uryu H
Ann Hematol; 2006 Aug; 85(8):542-4. PubMed ID: 16570152
[No Abstract] [Full Text] [Related]
2. Diminished alpha2-plasmin inhibitor activity associated with the use of imatinib mesylate in patients with Philadelphia chromosome-positive haematologic cancer.
Matsue K; Matsuo K; Fujiwara H; Iwama K; Hayama BY; Kimura S; Yamakura M; Takeuch M
Thromb Haemost; 2009 Jun; 101(6):1170-1. PubMed ID: 19492163
[No Abstract] [Full Text] [Related]
3. Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
Sonmez M; Cobanoglu U; Ovali E; Omay SB
J Clin Pharm Ther; 2008 Jun; 33(3):329-30. PubMed ID: 18452422
[No Abstract] [Full Text] [Related]
4. Gelatinous transformation of the bone marrow as a late morphological change in imatinib mesylate treated chronic myeloid leukaemia.
Hong FS; Mitchell CA; Zantomio D
Pathology; 2010 Jan; 42(1):84-5. PubMed ID: 20025487
[No Abstract] [Full Text] [Related]
5. Bone marrow necrosis secondary to imatinib usage, mimicking spinal metastasis on magnetic resonance imaging and FDG-PET/CT.
Aras Y; Akcakaya MO; Unal SN; Bilgic B; Unal OF
J Neurosurg Spine; 2012 Jan; 16(1):57-60. PubMed ID: 22017257
[TBL] [Abstract][Full Text] [Related]
6. Haemorrhagic complications associated with reduced alpha2-plasmin inhibitor during imatinib use in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Matsue K; Aoki T; Odawara J; Kimura S; Yamakura M; Takeuchi M
Leuk Res; 2009 Jun; 33(6):867-9. PubMed ID: 18951628
[No Abstract] [Full Text] [Related]
7. Bone marrow necrosis related to imatinib mesylate therapy for cml bilineal blast crisis.
Campiotti L; Codari R; Appio L; Ultori C; Solbiati F; Maria Grandi A; Venco A
Leuk Res; 2007 Dec; 31(12):1768-70. PubMed ID: 17403537
[No Abstract] [Full Text] [Related]
8. Adverse events after imatinib mesylate therapy.
Burton C; Azzi A; Kerridge I
N Engl J Med; 2002 Feb; 346(9):712-3. PubMed ID: 11873781
[No Abstract] [Full Text] [Related]
9. [Hypoprotidemia may explain imatinib intoxication in a patient with Philadelphia-positive acute lymphoblastic leukemia].
Gaïes E; Trabelsi S; Sahnoun R; Salouage I; Jebabli N; Charfi R; Lakhal M; Hdiji S; Klouz A
Therapie; 2013; 68(2):125-7. PubMed ID: 23773356
[No Abstract] [Full Text] [Related]
10. [Pediatric acute lymphoblastic leukemia initially presenting with bone marrow necrosis].
Kato M; Kikuchi A; Oshima K; Yamamoto S; Mochizuki S; Arai K; Hanada R
Rinsho Ketsueki; 2007 Feb; 48(2):140-3. PubMed ID: 17370642
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate as a cause of acute liver failure.
Cross TJ; Bagot C; Portmann B; Wendon J; Gillett D
Am J Hematol; 2006 Mar; 81(3):189-92. PubMed ID: 16493605
[TBL] [Abstract][Full Text] [Related]
12. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
13. Imatinib-induced Severe Hepatitis in a 9-Year-old Girl With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
Suzuki R; Kobayashi C; Sakai A; Fukushima H; Tagawa M; Satomi K; Nanmoku T; Sumazaki R; Fukushima T
J Pediatr Hematol Oncol; 2015 Aug; 37(6):e368-71. PubMed ID: 25929609
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia.
Fuster JL; Bermúdez M; Galera A; Llinares ME; Calle D; Ortuño FJ
Haematologica; 2007 Dec; 92(12):1723-4. PubMed ID: 18056006
[TBL] [Abstract][Full Text] [Related]
15. Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy.
Patel SB; Gojo I; Tidwell ML; Sausville EA; Baer MR
Leuk Lymphoma; 2011 Jul; 52(7):1211-4. PubMed ID: 21534873
[TBL] [Abstract][Full Text] [Related]
16. Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Dann EJ; Fineman R; Rowe JM
J Clin Oncol; 2002 Jan; 20(1):354-5. PubMed ID: 11773197
[No Abstract] [Full Text] [Related]
17. Prominent pleural effusion possibly due to imatinib mesylate in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ishii Y; Shoji N; Kimura Y; Ohyashiki K
Intern Med; 2006; 45(5):339-40. PubMed ID: 16596010
[No Abstract] [Full Text] [Related]
18. Vitiligo-like lesions in an adult patient treated with Imatinib mesylate.
Cerchione C; Fabbricini R; Pane F; Luciano L
Leuk Res; 2009 Aug; 33(8):e104-5. PubMed ID: 19232719
[No Abstract] [Full Text] [Related]
19. Systemic Mastocytosis: documented pathologic response to imatinib.
Gollard RP; Ruemmler-Fish C; Garcia D
Eur J Haematol; 2007 Oct; 79(4):367-8. PubMed ID: 17655701
[No Abstract] [Full Text] [Related]
20. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
Burke MJ; Cao Q; Trotz B; Weigel B; Kumar A; Smith A; Verneris MR
Pediatr Blood Cancer; 2009 Dec; 53(7):1289-94. PubMed ID: 19731318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
